Tyler Van Buren
Stock Analyst at TD Cowen
(2.30)
# 1,465
Out of 4,423 analysts
48
Total ratings
42.86%
Success rate
-0.56%
Average return
Main Sectors:
32 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Maintains: Buy | $90 → $85 | $64.58 | +31.62% | 4 | Apr 26, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,020 → $1,030 | $968.00 | +6.40% | 6 | Apr 24, 2024 | |
| BHVN Biohaven Pharmaceutical Holding Company | Maintains: Outperform | $35 → $55 | $41.36 | +32.98% | 1 | Mar 1, 2024 | |
| CRSP CRISPR Therapeutics AG | Downgrades: Underperform | $30 | $53.55 | -43.98% | 2 | Dec 11, 2023 | |
| CRGX CARGO Therapeutics | Initiates: Outperform | n/a | $19.00 | - | 1 | Dec 5, 2023 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | n/a | $35.19 | - | 1 | Nov 29, 2023 | |
| ACLX Arcellx | Initiates: Outperform | n/a | $52.73 | - | 1 | Oct 30, 2023 | |
| APGE Apogee Therapeutics | Initiates: Outperform | n/a | $52.92 | - | 1 | Aug 8, 2023 | |
| MRNA Moderna | Downgrades: Market Perform | $145 → $125 | $122.69 | +1.88% | 5 | Aug 4, 2023 | |
| SLRN Acelyrin | Initiates: Outperform | n/a | $4.88 | - | 1 | May 30, 2023 | |
| TVTX Travere Therapeutics | Initiates: Outperform | $30 | $6.60 | +354.55% | 1 | May 22, 2023 | |
| KROS Keros Therapeutics | Initiates: Outperform | n/a | $57.60 | - | 1 | Feb 14, 2023 | |
| BBIO BridgeBio Pharma | Initiates: Outperform | n/a | $28.73 | - | 1 | Feb 6, 2023 | |
| DCPH Deciphera Pharmaceuticals | Maintains: Outperform | $25 → $30 | $25.37 | +18.25% | 2 | Jan 25, 2023 | |
| FATE Fate Therapeutics | Downgrades: Market Perform | n/a | $3.90 | - | 2 | Jan 6, 2023 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $70 | $59.85 | +16.96% | 1 | Aug 8, 2022 | |
| ZNTL Zentalis Pharmaceuticals | Initiates: Outperform | n/a | $12.52 | - | 1 | Jul 12, 2022 | |
| ARVN Arvinas | Initiates: Outperform | n/a | $31.95 | - | 1 | Dec 7, 2021 | |
| TYRA Tyra Biosciences | Initiates: Outperform | n/a | $17.76 | - | 1 | Oct 11, 2021 | |
| EPIX ESSA Pharma | Initiates: Overweight | n/a | $6.25 | - | 1 | Mar 4, 2021 | |
| ALGS Aligos Therapeutics | Initiates: Overweight | n/a | $0.78 | - | 1 | Nov 10, 2020 | |
| BGNE BeiGene | Downgrades: Underweight | n/a | $168.64 | - | 2 | Nov 6, 2020 | |
| INZY Inozyme Pharma | Initiates: Overweight | n/a | $4.65 | - | 1 | Aug 18, 2020 | |
| NRIX Nurix Therapeutics | Initiates: Overweight | n/a | $13.95 | - | 1 | Aug 18, 2020 | |
| PSTX Poseida Therapeutics | Initiates: Overweight | n/a | $2.71 | - | 1 | Aug 4, 2020 | |
| LPTX Leap Therapeutics | Initiates: Overweight | n/a | $2.91 | - | 1 | Jun 29, 2020 | |
| PLRX Pliant Therapeutics | Initiates: Overweight | n/a | $13.81 | - | 1 | Jun 29, 2020 | |
| GOSS Gossamer Bio | Initiates: Overweight | n/a | $0.75 | - | 1 | Apr 22, 2020 | |
| TBPH Theravance Biopharma | Maintains: Overweight | n/a | $9.47 | - | 1 | Feb 25, 2020 | |
| ADVM Adverum Biotechnologies | Reiterates: Overweight | $140 → $200 | $9.61 | +1,981.17% | 1 | Jan 13, 2020 | |
| OMER Omeros | Downgrades: Market Perform | n/a | $3.56 | - | 1 | Nov 2, 2017 | |
| TEVA Teva Pharmaceutical | Downgrades: Market Perform | n/a | $16.00 | - | 1 | Aug 4, 2017 |
Gilead Sciences
Apr 26, 2024
Maintains: Buy
Price Target: $90 → $85
Current: $64.58
Upside: +31.62%
Regeneron Pharmaceuticals
Apr 24, 2024
Maintains: Buy
Price Target: $1,020 → $1,030
Current: $968.00
Upside: +6.40%
Biohaven Pharmaceutical Holding Company
Mar 1, 2024
Maintains: Outperform
Price Target: $35 → $55
Current: $41.36
Upside: +32.98%
CRISPR Therapeutics AG
Dec 11, 2023
Downgrades: Underperform
Price Target: $30
Current: $53.55
Upside: -43.98%
CARGO Therapeutics
Dec 5, 2023
Initiates: Outperform
Price Target: n/a
Current: $19.00
Upside: -
Spyre Therapeutics
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $35.19
Upside: -
Arcellx
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $52.73
Upside: -
Apogee Therapeutics
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $52.92
Upside: -
Moderna
Aug 4, 2023
Downgrades: Market Perform
Price Target: $145 → $125
Current: $122.69
Upside: +1.88%
Acelyrin
May 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $4.88
Upside: -
Travere Therapeutics
May 22, 2023
Initiates: Outperform
Price Target: $30
Current: $6.60
Upside: +354.55%
Keros Therapeutics
Feb 14, 2023
Initiates: Outperform
Price Target: n/a
Current: $57.60
Upside: -
BridgeBio Pharma
Feb 6, 2023
Initiates: Outperform
Price Target: n/a
Current: $28.73
Upside: -
Deciphera Pharmaceuticals
Jan 25, 2023
Maintains: Outperform
Price Target: $25 → $30
Current: $25.37
Upside: +18.25%
Fate Therapeutics
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $3.90
Upside: -
Immunocore Holdings
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $59.85
Upside: +16.96%
Zentalis Pharmaceuticals
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $12.52
Upside: -
Arvinas
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $31.95
Upside: -
Tyra Biosciences
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $17.76
Upside: -
ESSA Pharma
Mar 4, 2021
Initiates: Overweight
Price Target: n/a
Current: $6.25
Upside: -
Aligos Therapeutics
Nov 10, 2020
Initiates: Overweight
Price Target: n/a
Current: $0.78
Upside: -
BeiGene
Nov 6, 2020
Downgrades: Underweight
Price Target: n/a
Current: $168.64
Upside: -
Inozyme Pharma
Aug 18, 2020
Initiates: Overweight
Price Target: n/a
Current: $4.65
Upside: -
Nurix Therapeutics
Aug 18, 2020
Initiates: Overweight
Price Target: n/a
Current: $13.95
Upside: -
Poseida Therapeutics
Aug 4, 2020
Initiates: Overweight
Price Target: n/a
Current: $2.71
Upside: -
Leap Therapeutics
Jun 29, 2020
Initiates: Overweight
Price Target: n/a
Current: $2.91
Upside: -
Pliant Therapeutics
Jun 29, 2020
Initiates: Overweight
Price Target: n/a
Current: $13.81
Upside: -
Gossamer Bio
Apr 22, 2020
Initiates: Overweight
Price Target: n/a
Current: $0.75
Upside: -
Theravance Biopharma
Feb 25, 2020
Maintains: Overweight
Price Target: n/a
Current: $9.47
Upside: -
Adverum Biotechnologies
Jan 13, 2020
Reiterates: Overweight
Price Target: $140 → $200
Current: $9.61
Upside: +1,981.17%
Omeros
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $3.56
Upside: -
Teva Pharmaceutical
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $16.00
Upside: -